3Gritsch H,Rosenthal T,Danovitch GM.Living and cadaveric kidney donation,in Danovitch GM(ed):Handbook of Kidney Transplantation.第3版.北京:人民卫生出版社, 2001.
4Pescovitz MD, Conti D, Dunn J,et al. Intravenous mycophenolate mofeti l:Safety,tolerability, and pharmacokinetics. Clin Transplantation, 2000, 14:179.
5U.S renal transplant mycophenolate mofetil study group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995,60:225.
6Sonda K,Takahashi K,Tanabe K,et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc, 1996,28(6):3643.
7Motoyama O, Hasegawa A, Ohara T, et al.A prospective trial of steroid cessation after renal transplantation in pediatric patients treated with cyclosporine and mizoribine. Pediatr-Transplant, 1997,1(1):29.
8Samhan M, Al-Mousawi M, Al-Muzairai I, et al. Does recipient age affect the outcome of renal transplantation? Transplant Proc,2001, 33(5):2699.
9Ogawa N,Koyama i,Shibata T,et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. Proc.Transpl Proc, 1996,28(3):1394.
10Danovitch G,Deierhoi M,Ferguson R, et al. The MMF refractory rejection study group. Mycophenolate mofetil for the treatment of refractory,acute,cellular renal transplant rejection. Transplantation, 1996, 61(5):722.
